For the last 40 years, schizophrenia has been considered to be the result primarily of a dysfunction nitric oxide-mediated neurotransmission in schizophrenia. Studies were searched in PubMed, SciELO, and LILACS using the terms schizophrenia and nitric oxide plasma levels or nitric oxide serum levels, with no time limit. The reference lists of selected articles were also hand-searched for additional articles. From 15 potential reports, 10 were eligible to be included in the review and meta-analysis. These studies included a total of 505 patients with schizophrenia and 339 regarding total nitrite plasma/serum levels (effect size g = 0.285, 95%CI = -0.205 to 0.774, p = 0.254). However, when studies with patients under antipsychotic treatment were examined size g = 0.663, 95%CI = 0.365 to 0.961, p < 0.001), showing that patients under treatment have higher levels of plasma/serum nitric oxide than controls. These results suggest that antipsychotics increase nitric oxide plasma/serum levels and that the nitrergic pathway would be a fertile target for the development of new treatments for patients with schizophrenia.
Introduction
Schizophrenia is a devastating disorder that occurs in about 1% of the population throughout life. Individuals are usually affected somewhere between the end of adolescence and the beginning of adult life and the course of schizophrenia is chronic and debilitating.
1
For the last 40 years, schizophrenia was believed to be primarily the result of a dysfunction in brain dopaminergic pathways.
2 However, antipsychotic drugs that act as dopamine receptor antagonists have proven effective in treating only some of the symptoms of schizophrenia.
Recent research suggests that hypoactivity of a subtype of glutamatergic receptor, the N-methyl-D-aspartate (NMDA) receptor, may be involved in schizophrenia.
3, 4 One of the pieces of evidence supporting this hypothesis comes from the psychotic syndrome produced by NMDA receptor antagonists. This pharmacological model is the one that best mimics schizophrenia symptoms, as it induces both the positive and negative symptoms commonly seen in the disorder.
5-8 However, research on NMDA receptor agonists for the treatment of schizophrenia has produced inconsistent results
9
, possibly due to the development of rapid tolerance to these compounds secondary to down-regulation of NMDA receptors.
10
Accordingly, researchers have suggested the possible implication of nitric oxide (NO) in the pathophysiology of schizophrenia and other psychiatry disorders, such as bipolar disorder and depression.
11,12
NO is a gas with a unique chemistry and has been shown memory, and neurodevelopment. In addition, questions have been raised about whether NO plays an important role in the maturation of neurons and synaptogenesis. The activation of the cell, which binds to calmodulin and stimulates the neuronal nitric oxide synthase (nNOS) enzyme to produce NO in the nervous system. NO activates guanylate cyclase, which increases the levels of the second messenger cyclic GMP (cyclic guanosine monophosphate). This "NMDA-NO-cyclic GMP pathway" has been demonstrated to modulate the release of neurotransmitters such as glutamate and dopamine. Although the direction of abnormalities in this pathway is still under debate, it has been repeatedly implicated in schizophrenia, and perhaps the development of drugs that act downstream NMDA receptors -on NO for instance -could circumvent the problem of the down-regulation of those receptors.
12
In this review we describe empirical studies available in the literature that analyzed the role of NO in schizophrenia by examining NO plasma/serum levels in patients diagnosed with the condition.
Methods
The search was performed in the PubMed, SciELO, and LILACS databases using the keywords schizophrenia and nitric oxide plasma levels or nitric oxide serum levels, with no time limit. The reference lists of selected articles were also hand-searched for additional articles.
In order to be included in the analysis, studies had to meet the following criteria: 1) be published in any language; 2) include patients with schizophrenia diagnosed according to DSM-IV-TR criteria; 3) have a comparison group of healthy to indirectly assess NO plasma levels.
Since NO is a very labile molecule and has a short half-life, 13 In aqueous solution, NO reacts with molecular oxygen and accumulates in plasma/serum as nitrite (NO-2) and nitrate (NOhave been used as correlates of NO levels.
14 In most studies, plasma/serum NO metabolite levels are represented as total nitrite (nitrite + nitrate) after nitrate conversion to nitrite.
15
Among the studies analyzed in this review, 80% investigated differences in total nitrite plasma levels between schizophrenia patients and healthy volunteers, while the remaining 20% investigated differences in total nitrite serum levels between the two groups. Given the considerable agreement concerning the equivalence between serum and plasma concentrations of certain drugs and assuming that the same is true for NO, 16 we decided to analyze studies using plasma and serum as a single group.
Four studies measured patients' total nitrite levels at two different times -before and after antipsychotic treatment.
17-20
In these cases, we opted to work with measures obtained before antipsychotic treatment to ensure equivalence with the results of the remaining studies.
In order to select potentially relevant studies, three independent reviewers (JPMO, SI, CT) examined the abstracts inclusion criteria. Disagreement at any stage was resolved by consensus. The studies included in the review are summarized in Table 1 , which also describes the sociodemographic characteristics of the samples in each study.
Statistical analyses were performed with STATA 10.1 (StataCorp, College Station, Texas) using the METAN com--tervals were calculated. We used a random effects model that weighted the studies according to their inverse variance and provided the odds ratio and the corresponding The between-study variability among the population effect sizes, i.e. heterogeneity, was assessed formally by applying Cochran's q test for homogeneity 21 and informally by assessing a sample size independent descriptive measure of inconsistency I2. 22 The I2 index describes the percentage of the total variability in a set of effect sizes due to true heterogeneity, that is, between-study variability. 23 For example, a meta-analysis with I2 = 0 means that all variability in effect size estimates is due to sampling error within studies. On the other hand, a meta-analysis with I2 = 50 means that half of the total variability among effect sizes is caused not by sampling errors, but by true heterogeneity between studies. Higgins et al. 22 with the purpose of helping to interpret magnitude. Thus, percentages of around 25% (I2 = 25), 50% (I2 = 50), and 75% (I2 = 75) would indicate low, medium, and high heterogeneity, respectively. S151 NO in schizophrenia
Meta-regression
The effects of mean duration of illness on total nitrite plasma levels were assessed in a random effects meta-regression model by using the METAREG 25 command in STATA. The default option using residual maximum likelihood (REML) was selected.
To test how robust the results were to variations in the metaanalysis methodology, we examined the effect of excluding the two studies which evaluated NO serum levels instead of NO plasma levels.
17,26
Results inclusion criteria for this meta-analysis. One study was months of disease duration. Based on the diagnostic criteria of DSM-IV TR, at least six months of illness are required for schizophrenia to be diagnosed.
27 Four articles were excluded because they measured levels of individual NO metabolites rather than total nitrite levels.
28-31 Thus, 10 studies provided comparative data from patients versus controls (Table 1) .
Among the 10 studies analyzed in this review, all investigated differences in total nitrite plasma/serum levels between schizophrenia patients and healthy volunteers. The levels of plasma/serum total nitrite ranged from 3.37 ± between patients and healthy controls regarding total nitrite plasma/serum concentrations (effect size g = 0.285, 95%CI = -0.205 to 0.774, p = 0.254). Between-study heterogeneity (I2 = 90.8%, Q = 98.22, p < 0.001) was found, but there was no evidence of publication bias (p = 0.466). The effect of mean duration of illness (7 studies; r = 0.153; p = 0.005).
When studies with drug-free patients were evaluated between patients and healthy controls regarding total nitrite plasma/serum concentrations (effect size g = -0.109, 95%CI = -0.856 to 0.637, p = 0.774). There was between-study heterogeneity (I2 = 90.7%, Q = 43.01, p < 0.001), but no evidence of publication bias (p = 0.066). The meta-regression analysis showed no effect of duration of illness (4 studies; r = 0.147; p = 0.057). However, when we examined only the studies with padifference between patients and healthy volunteers (effect size g = 0.663, 95%CI = 0.365 to 0.961, p < 0.001), showing that patients under antipsychotic drug treatment have higher levels of plasma/serum total nitrite than controls. A moderate between-study heterogeneity (I2 = 56.0%, Q = 9.10, p = 0.059) was found and there was no evidence of publication bias (p = 0.819). The meta-regression analyses showed
All the results of this meta-analysis remained the same when we excluded the two studies which worked with NO serum levels: The meta-regression analysis showed no effect of duration of illness (4 studies; r = 0.147; p = 0.057).
Discussion
The neurobiology of schizophrenia is characterized by abnormalities in neurotransmission pathways including glutamate, GABA, and dopamine. 3, 33 The activation of glutamatergic stimulates nNOS to produce NO, which in turn activates guanylate cyclase resulting in increased production of cyclic GMP. Dysfunction in this "NMDA-NO-cyclicGMP" pathway has been implicated in schizophrenia.
34,35
Because the direction of abnormalities in this pathway is still under debate, in this meta-analysis we tried to better understand the role of NO in patients with schizophrenia by investigating whether there were differences in its plasma/ differences between patient groups and control groups reexplained by the presence of several studies with apparently contradictory results. Seven out of the 10 manuscripts found increased total nitrite levels in patients;
17,18,26,32,36-38 while the remaining three found the opposite.
1,9,20,39 Interestingly, all the reason why we detected between-study heterogeneity.
Methodological variations across the studies may be the explanation for this discrepancy. For example, the duration of disease could be a relevant factor for the levels of NO, given the possible adaptive mechanisms related to the evolution of symptoms. Seven out of 10 studies made reference to the duration of disease in the patient group and the effect of mean duration of illness, showing a positive correlation between the latter and levels of NO. In this regard, there are two studies in the literature that measured NO In addition, a study in which the patients spent a longer period without taking antipsychotic medication before the beginning of the trials (drug-free for at least four weeks) reported decreased total plasma nitrite levels in the patient group, and that six-week antipsychotic treatment with risperidone increased changes of nitrite plasma levels between baseline and the end of the treatment in the patient group were found and compared in PANSS score) and the 18 non-responders to treatment. Among responders, total plasma nitrite levels after treatment authors suggested that the improvement of psychiatric sympafter treatment. 19 Finally, three articles reported an increase schizophrenia after treatment with antipsychotic drugs.
41-43
As observed previously, the mechanism of action of NO involves increases in cyclic GMP concentrations through the activation of soluble guanylate cyclase.
Although plasma and serum are not the same thing and levels and NO plasma levels together could be regarded as generating a potential confounding factor in this study. Nonetheless, the sensitivity analyses indicated that this decision did not affect the main results of this meta-analysis. All the results of the meta-analysis remained the same when the two studies that evaluated NO serum levels were excluded. It is essential that future studies be more careful in controlling for potential confounding factors that are known to be relevant in schizophrenia. In this regard, well-designed studies must take into account variables such as disease duration and staging, schizophrenia subtype, tobacco use, and antipsychotic treatment. 44 Also, further studies should examine potential correlations between the intensity and quality of symptoms (as measured by scales like the PANSS), stage of disease, and plasma/serum levels of NO in schizophrenia patients.
Conclusion
High between-study heterogeneity was found and this could differences between the patient group and the control group regarding total nitrite plasma/serum levels. There were studies with apparently contradictory results and they could be divided into two groups: one group suggesting increased plasma/serum levels of total nitrites in patients when compared with healthy volunteers and another one supporting a possible decrease in such levels. It is thus likely that the results of one group were cancelled out by the results of the other.
tion between the duration of disease and levels of NO. In other words, the longer the duration of the disease is, the greater the NO levels in patients. We speculate that this could be explained both by pathophysiological differences between the acute and chronic phases of schizophrenia as well as by the use of medications along the course of the disease.
Lastly, patients under antipsychotic treatment were found to have higher levels of NO metabolites than controls. This nitrergic pathway by these drugs. It is believed that this pathway constitutes a fertile target for the development of new treatments for patients with schizophrenia. 
Resumo
Durante os últimos 40 anos, a esquizofrenia foi considerada, principalmente, como o resultado de disfunções dopaminérgicas no cérebro. Esta revisão descreve e discute algumas descobertas sobre a neurotransmissão mediada pelo óxido nítrico na esquizofrenia. A busca foi feita nas bases PubMed, SciELO e LILACS usando-se os termos schizophrenia e nitric oxide plasma levels ou nitric oxide serum levels, sem limites de tempo. As listas de referências dos artigos selecionados foram examinadas em busca de outras publicações pertinentes. Dentre 15 artigos passíveis de serem incluídos, 10 preenchiam os critérios estabelecidos para a revisão e metanálise. Esses estudos incluíram 505 pacientes com esquizofrenia e 339 voluntários saudáveis. Não foram encontradas de nitrito total (effect size g = 0,285, IC 95% = -0,205 a 0,774, p = 0,254). No entanto, o exame separado dos estudos envolvendo pacientes em tratamento antipsicótico apresentou diferenças effect size g = 0,663, IC 95% = 0,365 to 0,961, p < 0,001), demonstrando que pacientes em tratamento possuem níveis plasmáticos mais altos de óxido nítrico. Esses resultados sugerem que os antipsicóticos podem aumentar os níveis plasmáticos de óxido nítrico e que a via nitrérgica (e sua estimulação) constituiria um alvo propício para o desenvolvimento de novos tratamentos para pacientes com esquizofrenia. Pesquisas recentes sugerem que a hipoatividade de um subtipo do receptor glutamatérgico, o receptor N-metil-Dasparato (NMDA), pode estar envolvida na esquizofrenia. 3, 4 Uma das evidências em favor dessa hipótese advém da síndrome psicótica gerada pelos antagonistas do receptor NMDA. Esse modelo farmacológico é o que reproduz melhor os sintomas da esquizofrenia, uma vez que induz tanto sintomas positivos quanto negativos comumente observados na doença. [5] [6] [7] [8] No entanto, pesquisas sobre os agonistas do receptor NMDA para o tratamento da esquizofrenia tem produzido resultados inconsistentes, 9 consequência do down-regulation dos receptores NMDA. 10 Dessa forma, pesquisadores têm sugerido a possível implie de outras doenças psiquiátricas, tais como o transtorno bipolar e a depressão. 11, 12 O NO é um gás com uma química singular, que teve coma aprendizagem, a memória e o neurodesenvolvimento. Além -se. A ativação dos receptores NMDA pelo glutamato resulta e estimula a enzima óxido nítrico sintase neuronal (nNOS) a produzir NO no sistema nervoso. O NO ativa a guanilato ciclase, que eleva os níveis do segundo mensageiro, o GMP cíclico (monofosfato guanosina cíclico). Demonstrou-se que essa "via NMDA-NO-GMP cíclico" modula a liberação de neurotransmissores, tais como o glutamato e a dopamina. sendo debatida, ela tem sido repetidamente implicada na esquizofrenia e talvez o desenvolvimento de drogas que atuem mais adiante aos receptores NMDA -como no NO, por exemplo -possa evitar o problema de down-regulation desses receptores. 12 Nesta revisão são descritos estudos empíricos disponíveis na literatura que analisaram o papel de NO na esquizofrenia ao examinar os níveis plasmáticos/séricos do NO em pacientes diagnosticados com esse transtorno.
DESCRITORES:

Métodos
A busca foi feita nas bases PubMed, SciELO e LILACS usando--se os termos schizophrenia e nitric oxide plasma levels ou nitric oxide serum levels, sem limites de tempo. As listas de referências dos artigos selecionados também foram examinadas em busca de outras publicações pertinentes.
Para serem incluídos na análise, os estudos deveriam atender aos seguintes critérios: 1) ser publicado em qualquer língua; 2) incluir pacientes com esquizofrenia diagnosticada de acordo com os critérios de DSM-IV-TR (Diagnostic and Statistical Manual of Mental Disorders -fourth edition, text saudáveis; 4) medir os níveis plasmáticos (ou séricos) de nitrito total para avaliar indiretamente os níveis plasmáticos de NO.
Como a molécula de NO é muito instável e tem a meia vida curta, a detecção de NO em sua forma nativa é extremamente difícil. 13 Em solução aquosa, o NO reage com o oxigênio molecular e se acumula no plasma/soro como os íons nitrito (NO-2) e nitrato (NO-3). Esses íons podem ser medidos em de NO.
14 Na maioria dos estudos, os níveis plasmáticos/séricos de metabólitos de NO são representados como nitrito total (nitrito + nitrato) após a conversão de nitrato em nitrito. 15 Dentre os estudos analisados nesta revisão, 80% investigaram a diferença nos níveis plasmáticos de nitrito total entre pacientes com esquizofrenia e voluntários saudáveis, enquanto os 20% restantes investigaram as diferenças dos níveis séricos de nitrito total entre os dois grupos. Dada a concentrações séricas e plasmáticas de certas drogas, e supondo que o mesmo é verdadeiro para NO, 16 decidimos analisar estudos usando plasma e soro como um único grupo.
Quatro estudos mediram os níveis de nitrito total dos pacientes em dois momentos -antes e depois do tratamento com antipsicóticos. [17] [18] [19] [20] Nesses casos, optou-se por trabalhar com as medidas obtidas antes do tratamento com antipsicóticos, de modo a garantir a equivalência aos resultados dos outros estudos.
Para selecionar estudos potencialmente relevantes, três revisores independentes, (JPMO, SI e CT) examinaram os em qualquer estágio eram resolvidas através de consenso. Os estudos inclusos na revisão estão resumidos na Tabela 1, das amostras em cada estudo.
As análises estatísticas foram feitas com STATA 10.1 (StataCorp, College Station, Texas) usando o comando METAN. Para cada estudo, odds ratios de 95% foram calculados. Foi usado um modelo de efeitos odds ratio e o intervalo de A variabilidade entre os estudos dentre os tamanhos de efeito da variabilidade total da população, isto é, a heterogeneidade, foi avaliada formalmente, por meio da aplicação do teste q de Cochran para a homogeneidade 21 e, informalmente, por meio da avaliação da medida descritiva de inconsistência independente de tamanho da amostra I2. Foi usado o teste de regressão de Egger, que é um método formal para avaliar o viés de publicação, 24 implementado com a função METABIAS do STATA.
Metarregressão
Os efeitos da duração média da doença sobre os níveis plasmáticos de nitrito total foram avaliados de acordo com um modelo de metarregressão de efeitos randomizados usando o comando METAREG 25 do STATA. A opção padrão usando a máxima probabilidade residual (REML) foi selecionada.
Análise de sensibilidade
Para testar o quão expressivos eram os resultados em relação às variações na metodologia de metanálise, examinou-se o efeito de exclusão dos dois estudos que avaliaram os níveis séricos de NO em vez dos níveis plasmáticos de NO.
17,26
Resultados
A busca gerou artigos, dos quais 10 atendiam aos ctritérios para esta metanálise. Um estudo foi excluído por causa menos de seis meses. Com base nos critérios de diagnóstico de DSM-IV-TR, são necessários pelo menos seis meses de sintomas da doença para se diagnosticar a esquizofrenia.
27
Quatro artigos foram excluídos porque mediam níveis de metabólitos individuais de NO, em vez dos níveis de nitrito total. [28] [29] [30] [31] Assim, 10 estudos forneceram dados comparativos dos pacientes versus controles (Tabela 1).
Dentre os 10 estudos analisados nesta revisão, todos investigaram as diferenças quanto aos níveis plasmáticos/ séricos de nitrito total entre pacientes com esquizofrenia e voluntários saudáveis. Os níveis plasmáticos/séricos de nitrito 
Discussão
A neurobiologia da esquizofrenia é caracterizada por anormalidades em vias de neurotransmissão, incluindo o glutamato, GABA (ácido gama-aminobutírico) e dopamina. 3, 33 A ativação que estimula a nNOS a produzir NO, que, por sua vez, ativa a guanilato ciclase, resultando em produção elevada de GMP cíclico. A disfunção na via "NMDA-NO-GMP cíclico" tem sido relacionada com a esquizofrenia. 34, 35 Como a direção das anormalidades nessa via ainda está sendo debatida, nesta metanálise tentamos entender melhor o papel de NO em pacientes com esquizofrenia ao investigar se havia diferenças nas concentrações plasmáticos/séricas esquizofrenia e controles saudáveis.
Dentre os 10 estudos selecionados, não houve diferen- 44 Ainda, novos estudos deveriam examinar possíveis correlações entre a intensidade e a qualidade dos sintomas (conforme medições em escalas como a PANSS), o estágio da doença e os níveis plasmáticos/séricos de NO em pacientes esquizofrênicos.
Conclusão
Foi encontrada elevada heterogeneidade entre os estudos, o que poderia ser responsável pela descoberta da metanálise pacientes e o grupo controle quanto aos níveis plasmáti-coséricos de nitrito total. Havia estudos que apresentavam resultados aparentemente contraditórios, que poderiam ser divididos em dois grupos: um sugerindo um aumento dos níveis plasmáticos/séricos de nitrito total em pacientes, quando comparados a voluntários saudáveis e um que apoia uma possível diminuição de tais níveis. É, portanto, provável que os resultados de um grupo tenham sido anulados pelos do outro.
Uma das descobertas desta revisão foi uma correlação positiva entre a duração da doença e os níveis de NO. Em outras palavras, quanto mais longa a doença, maiores são os níveis de NO nos pacientes. Especulamos que isso poderia medicações ao longo do curso da doença. com antipsicóticos apresentam níveis mais altos de metabó-litos de NO do que os controles. Essa descoberta pode estar relacionada a um possível estímulo da via nitrérgica por essas drogas. Acreditamos que essa via constitui um alvo propenso ao desenvolvimento de novos tratamentos para pacientes com esquizofrenia. 
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